Oxford Gene Technology (OGT) introduces the NGS SureSeq™ CLL + CNV V3 Panel, a powerful tool tailored for contract testing laboratories focusing on chronic lymphocytic leukemia (CLL). By incorporating proprietary bait designs and expanded gene coverage, this panel ensures comprehensive detection of disease-associated variants, enabling precise classification and analysis of research samples.
Designed with input from top clinical researchers, this panel excels in both sensitivity and accuracy. Recent trials demonstrated 100% detection of expected TP53 SNVs, with variant allele frequencies as low as 1–5%, and CNV detection down to 20% tumor content. The integration with OGT’s Interpret software simplifies bioinformatics analysis, making the panel accessible for labs of all sizes and expertise levels.
Why contract labs choose SureSeq™ CLL + CNV V3:
- High Sensitivity: Detects low-frequency SNVs with unparalleled precision.
- Reliable CNV Analysis: Reduces inter-run variability with internal reference DNA.
- Efficiency: Complements lab workflows with rapid sample-to-result processing.
- Simplified Bioinformatics: Includes free software to streamline NGS data analysis.
This advanced panel empowers contract testing labs to deliver actionable insights with improved confidence, fostering stronger collaborations with research partners.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: “OGT unveils the enhanced SureSeq CLL + CNV V3 Panel for deeper insights into CLL progression“
